TMCnet News
Biofidelity announces first peer reviewed publication of breakthrough ASPYRE™ technologyCAMBRIDGE, United Kingdom, March 23, 2021 (GLOBE NEWSWIRE) -- Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE™ technology has been published in Scientific Reports, a Nature journal. The article, titled "Single-copy detection of somatic variants from solid and liquid biopsy" is freely available online at www.nature.com/articles/s41598-021-85545-3. As well as detailing the novel technology behind ASPYRE™, the publication evidences the flexibility of Biofidelity's breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer. Highlights of the publication include:
Dr. Barnaby Balmforth, Chief Executve Officer of Biofidelity, commented: "The publication of data on ASPYRE™ in the highly respected Scientific Reports Journal is another important step forward in bringing this breakthrough technology to the market. The article provides evidence and validation of our approach to enable many more cancer patients to benefit from precision diagnostics. We are grateful for the support of Agilent, one of Biofidelity's early investors and collaborators, in helping us to complete this study." About Biofidelity For more information, please go to www.biofidelity.com For enquiries, please contact:
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. |